Efficacy of sequential denosumab after teriparatide for 6 months compared with denosumab monotherapy in reducing risk of osteoporotic fractures in patients with new fractures: a multicentre randomised controlled trial (STAND study) protocol. [PDF]
BMJ OpenChi Y +14 more
europepmc +1 more source
Comparative safety of denosumab and romosozumab in osteoporosis: an analysis based on the FDA adverse event reporting system database. [PDF]
Front Med (Lausanne)Sun J, Lunzhu C, Wu Y, Li J.
europepmc +1 more source
Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report [PDF]
, 2015 Allen R. Hendricks +5 more
core +1 more source
A Randomized Phase 1 Study Comparing the PK, PD, Safety, and Immunogenicity of Proposed Biosimilar RGB-14-X and Denosumab in Healthy Adult Males. [PDF]
Clin Transl SciBiver E +11 more
europepmc +1 more source
Multiple Vertebral Fractures After One Dose of Denosumab. [PDF]
AACE Endocrinol DiabetesRyan JL, Eldeiry LS.
europepmc +1 more source
Hypercalcemia after denosumab discontinuation in patients with osteoporosis: a systematic review and case report. [PDF]
Osteoporos IntMenéndez JQ +3 more
europepmc +1 more source
Phase III Study to Confirm Clinical Similarity of MB09, a Denosumab Biosimilar, and Prolia<sup>®</sup> in Postmenopausal Women with Osteoporosis (SIMBA Study). [PDF]
PharmaceuticsSupronik J +6 more
europepmc +1 more source
SEOM Clinical Guideline for bone metastases from solid tumours (2016) [PDF]
, 2016 core +1 more source
Idiopathic Hypoparathyroidism in an Osteoporosis Patient Receiving Denosumab Therapy. [PDF]
CureusYang LS, Tokunaga DS, Lim SY.
europepmc +1 more source
Giant Cell Tumor of Bone: Biology, Pathophysiology, and Histopathology in the Era of H3F3A. [PDF]
BiomedicinesCarneiro BD +4 more
europepmc +1 more source